Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…
Gastroesophageal Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
Immune checkpoint inhibitors Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) and Keytruda (Merck & Co.) have revolutionized the treatment of gastroesophageal cancer, driving substantial market…
Gastroesophageal Cancer – Current Treatment – Current Treatment: Physician Insights – Gastroesophageal Cancer (US)
The gastroesophageal cancer therapy market is gaining a lot of traction. In the HER2-positive segment, trastuzumab-based regimens, with or without Keytruda, continue to dominate. Meanwhile, the…
Gastroesophageal Cancer – Current Treatment – Treatment Sequencing – Gastroesophageal Cancer (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Gastroesophageal Cancer – Unmet Need – Unmet Need – Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (US/EU)
Approximately 40% of gastric and gastroesophageal junction (GEJ) adenocarcinoma patients present with metastasis, and half of patients with localized disease progress to metastatic disease…
